Short answer
Foghorn Therapeutics Inc. (FHTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $84M (up 924.7% year over year) with net income of $58M.
Q3 2026 key financials · XBRL
- Revenue
- $84M
- +924.7% YoY · +419.8% QoQ
- Net income
- $58M
- +466.9% YoY · +908.6% QoQ
- Operating margin
- 67.8%
- EPS (diluted)
- $0.82
- +415.4% YoY · +920.0% QoQ
Source: XBRL data from the Foghorn Therapeutics Inc. (FHTX) Q3 2026 10-Q on SEC EDGAR. USD.
Foghorn Therapeutics Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $83.5M, up $75.4M YoY from $8.2M, including $74.1M cumulative catch-up adjustment
- Operating margin 67.8% vs negative 226.9% YoY, with operating income $56.6M vs loss of $18.5M
- Lilly partnered programs, largest R&D line, $4.6M, down $2.2M YoY; early development costs increased $1.7M
- Cash, equivalents and marketable securities $156.2M; nine-month operating cash outflow $61.4M
- Near-term cost reductions expected from pipeline reprioritization and 40% workforce reduction; cash runway expected at least twelve months
Risk Factors
- New clinical-development risk: FHD-909 and SMARCA2 degrader halted after Phase 1 data review
- New workforce-reduction risk: strategic reprioritization cut approximately an undisclosed percentage of employees
- Regulatory risk: IRS audit opened for tax year 2023, with potential outcomes under evaluation
- Financial risk: accumulated deficit $601.4 million despite $31.1 million nine-month net income
- Collaboration concentration risk: $74.1 million revenue recognized from Lilly program reprioritization નિર્ણ
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Foghorn Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.